# France Infertility Market

> France Infertility Market Research Report By Sex (Males, Females, Unexplained), By Diagnosis (Men Diagnostic Tests, Women Diagnostic Tests, General Diagnostic Test), By Drugs (Clomiphene Citrate, Letrozole, Serophene, Hormone Treatment, Others) andBy Technology (Assisted Reproductive Technology, Intrauterine Insemination, Surgery) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 12.79%
- **2024:** $ 91.59 Million
- **2025:** $ 103.3 Million
- **2035:** $ 344.2 Million
- **Key Players:** CooperSurgical (US), Merck KGaA (DE), Ferring Pharmaceuticals (CH), Vitrolife (SE), Irvine Scientific (US), Reproductive Health Technologies (US), OvaScience (US), Genea (AU)

**Report ID:** MRFR/HC/43843-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/france-infertility-market-45523

---

## Market Summary

## **France Infertility Market Overview**

As per MRFR analysis, the France Infertility Market Size was estimated at 81.37 (USD Million) in 2024The France Infertility Market Industry is expected to grow from 91.8(USD Million) in 2025 to 415.0 (USD Million) by 2035. The France Infertility Market CAGR (growth rate) is expected to be around 14.7% during the forecast period (2025 - 2035).

**Key France Infertility Market Trends Highlighted**

The France infertility market is currently experiencing notable shifts driven by various factors. One primary market driver is the increasing awareness and acceptance of assisted reproductive technologies among the French population. With a rise in infertility issues partly attributed to lifestyle changes and delayed parenthood, many couples are seeking medical assistance. The French government has also played a role by recently revising its laws to broaden access to fertility treatments, making it easier for a wider demographic, including same-sex couples and single women, to consider assisted reproduction.

This legal support enhances the marketability of infertility services, leading to an upsurge in demand.

Opportunities in the France infertility market are significant, particularly in the realm of personalized medicine and advanced reproductive technologies. There is a growing interest in addressing individual patient needs through tailored treatment plans that consider genetic factors and lifestyle choices. This is complemented by an increase in the collaboration between healthcare providers and technology firms, leading to innovations in fertility preservation solutions and improved monitoring of patients undergoing treatment. 

In recent times, trends such as increased utilization of telehealth services for fertility consultations have emerged, reflecting a shift toward convenience and accessibility in healthcare.The COVID-19 pandemic accelerated this trend as patients sought safer alternatives to in-person visits. Furthermore, the ongoing emphasis on mental health within reproductive care is reshaping service approaches, focusing on providing psychological support during the fertility journey. These trends indicate a market that is evolving rapidly to meet the changing needs of patients seeking infertility solutions in France.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**France Infertility Market Drivers**

**Increasing Prevalence of Infertility**

The prevalence of infertility is on the rise in France, largely due to increasing age of first-time parents and lifestyle choices. According to the French National Institute of Health and Medical Research (INSERM), approximately 15% of couples in France face fertility issues, a statistic that reflects growing public health concerns.

Moreover, a report from the French Ministry of Health indicates that age-related fertility decline has pushed the average age of first pregnancy to 30 years, which correlates with higher incidences of infertility.This trend is expected to boost the France Infertility Market Industry as more couples will seek reproductive assistance such as IVF and other fertility treatments.

**Advancements in Reproductive Technologies**

Technological advancements in reproductive health have significantly enhanced the success rates of infertility treatments. There has been an increase in the number of fertility clinics in France, with organizations like the French Society of Reproductive Medicine advocating for the adoption of advanced techniques. For instance, data from theAgence de la Biomédecine (ABM) indicates that the success rates for IVF procedures have improved by 30% over the last decade, contributing to overall growth in the France Infertility Market.These advancements not only attract more couples seeking treatment but also encourage further investments in the industry.

**Government Support and Policy Changes**

The French government has become increasingly proactive in addressing infertility issues by extending coverage for various assisted reproductive technologies. Recent reforms by the Ministry of Health have expanded access to fertility treatments for same-sex couples and single women, which plays a crucial role in the accessibility of infertility services. As per the French government, these changes have led to increased enrollment in fertility programs, potentially driving market growth in the France Infertility Market Industry.Such systemic support showcases the commitment to enhancing reproductive health and can lead to a surge in demand for infertility solutions across the country.

**France Infertility Market Segment Insights**

**Infertility Market Sex Insights**

The France Infertility Market is witnessing significant dynamics within the Sex segment, which includes Male, Female, and Unexplained factors contributing to infertility. As societal norms evolve, there is an increased awareness and focus on fertility issues, leading to greater engagement in reproductive health discussions. The increasing incidence of infertility issues among couples in France has driven demand for innovative treatments and solutions. In this context, the Male infertility segment has gained prominence due to the rising acknowledgment of male reproductive health problems linked to lifestyle and environmental factors.

Female infertility remains a critical aspect, significantly influenced by factors such as age, health conditions, and lifestyle choices, leading to a growing inclination toward fertility preservation methods among women. Additionally, a considerable proportion of infertility cases remain unexplained, underscoring the need for ongoing research and development in this area. This ambiguity presents both challenges and opportunities for healthcare providers and researchers in France, pushing for the development of more advanced diagnostic tools and treatment protocols.

The France Infertility Market segmentation reflects the urgent need for collaboration between healthcare professionals, institutions, and policymakers to address these complex issues. Overall, the Sex segment plays a vital role within the broader France Infertility Market, highlighting multifaceted aspects of reproductive health that require comprehensive attention and strategic efforts to improve outcomes for affected individuals.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Infertility Market Diagnosis Insights**

The Diagnosis segment of the France Infertility Market plays a critical role in the overall understanding and treatment of infertility issues within the region. This segment encompasses various tests, including Men Diagnostic Tests, Women Diagnostic Tests, and General Diagnostic Tests, each designed to address specific factors contributing to infertility. Men Diagnostic Tests are vital as they assess parameters like sperm count and quality, which significantly influence male fertility levels. Women Diagnostic Tests focus on evaluating ovulatory function, hormonal imbalances, and anatomical conditions, making them essential for identifying female infertility causes.

Moreover, General Diagnostic Tests provide a comprehensive approach, enabling healthcare providers to screen for underlying health issues affecting both men and women. The growing awareness about infertility issues and advancements in diagnostic technologies are contributing to market growth. Furthermore, France’s healthcare system supports innovative solutions and easy access to testing, propelling the demand for these diagnostic assessments. With a rising number of couples seeking assistance for infertility, the importance of accurate diagnosis cannot be overstated, as it lays the groundwork for effective treatment plans in this evolving medical landscape.

**Infertility Market Drugs Insights**

The Drugs segment of the France Infertility Market plays a crucial role in the overall healthcare landscape, especially as infertility becomes a growing concern among couples in France. Clomiphene Citrate and Letrozole are among the most notable oral medications used commonly to induce ovulation, thus holding a significant share due to their effectiveness and accessibility. Serophene, often used to treat hypogonadism, also contributes significantly to the overall treatment approaches. Hormone Treatments, including those involving progesterone and estrogen, cater to various hormonal imbalances that contribute to infertility.

As the market continues to evolve, innovations and research are expected to further enhance the efficacy of these treatments. The increasing awareness about infertility treatment options and supportive healthcare policies in France contribute to the growth and acceptance of these Drugs. Additionally, the presence of a robust healthcare infrastructure ensures that patients have access to a variety of medications, reinforcing the importance of this segment in providing comprehensive care and contributing positively to the France Infertility Market data and statistics.

**Infertility Market Technology Insights**

The Technology segment of the France Infertility Market is showing a robust evolution in addressing the increasing demand for effective infertility solutions. With a significant focus on Assisted Reproductive Technology, including in-vitro fertilization (IVF), this segment plays a crucial role in enhancing reproductive outcomes for couples facing infertility challenges. Intrauterine Insemination emerges as another vital technique, known for its accessibility and effectiveness in simplifying the conception process for many, thereby making it a preferred choice among individuals seeking assistance.

Surgical interventions related to infertility, encompassing various procedures aimed at correcting anatomical issues or enhancing reproductive function, also contribute significantly to the overall enhancements in fertility treatments. The growth of these technologies is driven by factors such as rising awareness, advancements in medical technology, and favorable governmental policies in France supporting fertility treatments. However, issues such as the high costs associated with advanced fertility procedures and limited insurance coverage present challenges that the market must navigate.

Overall, the segmentation within the Technology sector signifies a comprehensive approach to tackling infertility, marking a notable shift in the reproductive health landscape in France.

**France Infertility Market Key Players and Competitive Insights:**

The France Infertility Market is experiencing significant growth, driven by increasing awareness about reproductive health, advancements in assisted reproductive technologies, and rising infertility rates. The competitive landscape in this market is characterized by a diverse range of players, including healthcare providers, pharmaceutical companies, and fertility clinics. These entities focus on offering innovative treatments, diagnostic tools, and supportive care services to cater to the unique needs of individuals and couples facing infertility challenges. As technological advancements continue to evolve, the competition among these players is intensifying, leading to better solutions and improved patient experiences throughout France.

Biogena has established a strong foothold in the France Infertility Market by leveraging its extensive product portfolio and commitment to quality. With a focus on providing advanced supplements and fertility-related products, Biogena stands out for its evidence-based approach and rigorous quality control measures. The company has built a reputation for effectively addressing nutritional deficiencies that can impact reproductive health, driving demand for its offerings among healthcare professionals and patients alike.

Biogena's strong distribution network, combined with its emphasis on education and healthcare partnerships, has enabled it to gain significant market presence and effectively focus on the fertility needs of the French population.

Eugin Group has carved out a notable presence in the France Infertility Market, offering a comprehensive suite of services that include in vitro fertilization (IVF), egg donation, and personalized fertility treatments. Its competitive advantages stem from a robust clinical framework, innovative technologies, and a strong emphasis on patient care. Eugin Group collaborates with various medical institutions to enhance its service offerings, ensuring high success rates and patient satisfaction. 

The company has also engaged in strategic mergers and acquisitions to expand its capabilities and strengthen its market position in France, facilitating access to cutting-edge treatments and enhancing its service portfolio. With a focus on creating a seamless patient journey, Eugin Group continues to solidify its standing as a leader in the infertility treatment landscape within the country.

**Key Companies in the France Infertility Market Include**

**France Infertility Market Industry Developments**

In recent months, the France Infertility Market has witnessed significant movements, particularly involving key players such as Eugin Group and IBIS ART. Eugin Group announced an expansion of their services in May 2023, aiming to enhance patient access to IVF treatments across France. Fertility Network UK and the French Fertility Society have been collaborating on awareness campaigns to educate the public about fertility challenges, promoting a more informed approach towards treatment options.

Notably, IBIS ART has reported a valuation increase due to advancements in reproductive technology, contributing positively to the overall market dynamics. In terms of mergers and acquisitions, Clinique de la Femme was in talks regarding a potential merger with Fertinova in June 2023, enhancing their service portfolio. Toulouse Fertility Center has also seen growth in its market valuation driven by government support for fertility treatments, which was emphasized in the 2022 health initiative that allocated additional funds to reproductive health services.

These developments indicate a robust and evolving landscape in the French infertility sector, underscoring both corporate growth and increased public engagement in reproductive health issues.

**France Infertility Market Segmentation Insights**

**Infertility Market****Sex****Outlook**

**Infertility Market****Diagnosis****Outlook**

**Infertility Market****Technology****Outlook**

## Market Drivers

### Rising Infertility Rates

The infertility market in France is experiencing growth due to rising infertility rates among couples. Recent data indicates that approximately 15% of couples in France face difficulties in conceiving, which has led to an increased demand for fertility treatments and services. This trend is further exacerbated by lifestyle factors such as delayed childbearing, obesity, and environmental influences. As more individuals seek assistance, the infertility market is likely to expand, with a projected growth rate of around 5% annually. This increase in demand for reproductive health services is prompting healthcare providers to enhance their offerings, thereby driving innovation and investment in the infertility market.

### Government Support and Funding

Government initiatives play a crucial role in shaping the infertility market in France. The French government has implemented various policies aimed at supporting couples facing infertility challenges. For instance, the reimbursement of assisted reproductive technologies (ART) has been expanded, covering treatments such as in vitro fertilization (IVF) for women up to 43 years old. This financial support not only alleviates the economic burden on couples but also encourages more individuals to seek treatment. As a result, the infertility market is likely to see increased participation, with an estimated 30% of couples utilizing ART services due to government backing.

### Increased Access to Fertility Clinics

The accessibility of fertility clinics in France is a significant driver of the infertility market. Over the past few years, there has been a notable increase in the number of fertility clinics, particularly in urban areas. This expansion has made it easier for couples to access reproductive health services, reducing geographical barriers to treatment. Additionally, many clinics are adopting patient-centered approaches, offering personalized care and support throughout the treatment process. As access improves, it is expected that more couples will pursue fertility treatments, potentially leading to a 25% increase in the utilization of infertility services in the near future.

### Cultural Shifts Towards Family Planning

Cultural attitudes towards family planning are evolving in France, impacting the infertility market. There is a growing acceptance of assisted reproductive technologies as viable options for family building. This shift is partly driven by changing societal norms, where individuals prioritize career and personal development before starting families. Consequently, many couples are delaying parenthood, which can lead to increased infertility issues. As awareness of fertility preservation options rises, the infertility market is likely to benefit from a surge in demand for services, with an anticipated growth of 4% in the coming years as more couples seek assistance.

### Advancements in Reproductive Technologies

Technological innovations are significantly influencing the infertility market in France. The introduction of advanced reproductive technologies, such as preimplantation genetic testing (PGT) and cryopreservation techniques, has improved success rates for fertility treatments. These advancements allow for better selection of viable embryos and preservation of fertility for individuals facing medical conditions or age-related challenges. As these technologies become more accessible, the infertility market is expected to grow, with a potential increase in treatment success rates by up to 20%. This progress not only enhances patient outcomes but also attracts more individuals to seek [fertility services](https://www.marketresearchfuture.com/reports/fertility-services-market-6281).

## Future Outlook

The [Infertility Market](https://www.marketresearchfuture.com/reports/infertility-market-6145) in France is projected to grow at a 12.79% CAGR from 2025 to 2035, driven by technological advancements, increasing awareness, and rising infertility rates.

**New opportunities:**

- Development of AI-driven fertility tracking applications
- Expansion of telehealth services for remote consultations
- Investment in advanced reproductive technologies like CRISPR

By 2035, the infertility market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Type: Assisted Reproductive Technology (Largest) vs. Hormone Therapy (Fastest-Growing)

In the France infertility market, Assisted Reproductive Technology (ART) holds the largest share among the segment values, indicating a strong preference for technologically advanced solutions in addressing infertility. Other segments such as Hormone Therapy, Surgery, and Fertility Preservation are also significant but occupy smaller shares of the market, reflecting varying preferences among patients seeking treatments across these different modalities.

The growth trends in the France infertility market show a shift towards Hormone Therapy as the fastest-growing segment. Factors contributing to this trend include the increasing awareness of hormonal imbalances affecting fertility and the expanding availability of innovative therapies & treatments. The demand for ART remains robust as couples seek effective and holistic approaches to overcome infertility challenges, and the rising trend of fertility preservation is indicative of changing societal attitudes toward family planning and reproductive health.

Assisted Reproductive Technology (Dominant) vs. Hormone Therapy (Emerging)

Assisted Reproductive Technology (ART) remains the dominant solution in the France infertility market, characterized by its comprehensive range of services, including in-vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI). It caters to couples facing various infertility issues and is supported by ongoing advancements in technology that enhance success rates. On the other hand, Hormone Therapy is emerging as a crucial method, particularly for addressing specific hormonal deficiencies and imbalances, which have been increasingly recognized as significant contributors to fertility issues. This segment is gaining traction due to the introduction of personalized medicine approaches, allowing treatments to be tailored to individual hormonal profiles, thus promising better outcomes in the fertility journey.

### By End User: Fertility Clinics (Largest) vs. Hospitals (Fastest-Growing)

In the France infertility market, the segment distribution reveals that Fertility Clinics hold the largest share, driven by a combination of specialized services and increasing patient preference for dedicated facilities. Hospitals, while currently trailing behind in market share, are emerging as a significant player due to their comprehensive healthcare offerings that often integrate infertility treatment with other services, catering to a wider audience. 

Growth trends indicate a rising demand for both Fertility Clinics and Hospitals, fueled by increasing public awareness regarding infertility issues and advancements in reproductive technologies. Fertility Clinics are capitalizing on specialized treatments, while Hospitals are expanding their capabilities to include more robust infertility services. This dual approach enhances accessibility and meets the diverse needs of patients across various demographics.

Fertility Clinics (Dominant) vs. Hospitals (Emerging)

Fertility Clinics, as the dominant segment in the France infertility market, specialize in a range of services from diagnostics to advanced reproductive techniques, making them a preferred choice for patients seeking tailored care. Their focus on personalized treatment plans and state-of-the-art technologies allows them to maintain leadership in patient satisfaction and success rates. On the other hand, Hospitals are emerging as prominent players by leveraging their expansive resources and integrated healthcare services. They are gradually recognizing the growing need for infertility treatment and are actively investing in specialized departments. This shift not only broadens their service offerings but also positions them to capture a greater share of the patient population that may initially seek infertility solutions in conventional healthcare settings.

### By Gender: Female (Largest) vs. Male (Fastest-Growing)

The market share distribution for the France infertility market reveals that the female segment holds a significant majority, emphasizing the critical role of women in addressing infertility issues. This dominance is driven by various factors, including higher healthcare engagement and a greater number of treatment options available for females, contributing to their substantial presence in the market.

On the other hand, the male segment is emerging as the fastest-growing area within the France infertility market. This rise can be attributed to a growing awareness of male infertility factors, an increase in available treatments, and changing societal norms surrounding family planning. The focus on male health and fertility solutions is expected to continue driving growth in this segment over the coming years.

Female (Dominant) vs. Male (Emerging)

The female segment in the France infertility market is characterized by a robust market presence and a wide array of treatment options, including IVF, ovulation induction, and hormonal therapies. Females seeking assistance often engage in comprehensive treatment plans that cover various aspects of reproductive health, thus making this segment dominant. Conversely, the male segment, while currently smaller, is in a phase of rapid growth as awareness around male infertility issues rises. Innovations in treatments and a societal shift towards recognizing men's reproductive health needs position the male segment as an emerging area of focus, appealing to a broader audience as educational efforts continue.

### By Cause of Infertility: Ovulatory Disorders (Largest) vs. Male Factor Infertility (Fastest-Growing)

Among the various causes of infertility, ovulatory disorders hold the largest market share, dominating the landscape due to a higher prevalence in affected populations. These disorders are often linked to hormonal imbalances, making them a critical focus for treatment and research in the France infertility market.

In contrast, male factor infertility is recognized as the fastest-growing segment, driven by increasing awareness and reduced stigma around male reproductive health. Factors such as lifestyle changes and environmental influences have contributed to the rise in male infertility cases, pushing the market toward innovative treatment solutions.

Ovulatory Disorders (Dominant) vs. Male Factor Infertility (Emerging)

Ovulatory disorders are characterized by irregular ovulation or absence of ovulation, which significantly impacts fertility in women. This dominant cause is primarily treated through hormonal therapies and lifestyle modifications, positioning it as a well-established segment with a robust patient base. Conversely, male factor infertility, though emerging, is rapidly gaining attention as research uncovers the complexities of male reproductive health. As societal topics surrounding male fertility evolve, there is a growing demand for advanced diagnostics and treatments, making this segment crucial for future developments in the France infertility market.

## Competitive Benchmarking

The infertility market in France is characterized by a dynamic competitive landscape, driven by increasing awareness of reproductive health and advancements in assisted reproductive technologies (ART). Key players such as CooperSurgical (US), Merck KGaA (DE), and Ferring Pharmaceuticals (CH) are strategically positioned to leverage innovation and partnerships to enhance their market presence. CooperSurgical (US) focuses on expanding its product portfolio through acquisitions, while Merck KGaA (DE) emphasizes research and development to introduce cutting-edge solutions. Ferring Pharmaceuticals (CH) is actively pursuing collaborations with healthcare providers to improve patient access to fertility treatments, thereby shaping a competitive environment that prioritizes patient-centric approaches.
In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market structure appears moderately fragmented, with several players vying for market share. The collective influence of these key players fosters a competitive atmosphere where innovation and strategic partnerships are paramount for success.
In October 2025, Merck KGaA (DE) announced a strategic partnership with a leading French fertility clinic to develop personalized treatment plans utilizing AI-driven analytics. This collaboration is expected to enhance patient outcomes by tailoring therapies to individual needs, thereby reinforcing Merck's commitment to innovation in reproductive health. The strategic importance of this partnership lies in its potential to set new standards in personalized medicine within the infertility sector.
In September 2025, Ferring Pharmaceuticals (CH) launched a new fertility medication aimed at improving success rates in IVF procedures. This product introduction is significant as it reflects Ferring's dedication to addressing unmet needs in the market. By expanding its product offerings, Ferring positions itself as a leader in providing comprehensive solutions for fertility challenges, which may enhance its competitive edge.
In August 2025, CooperSurgical (US) completed the acquisition of a European biotech firm specializing in reproductive genetics. This acquisition is likely to bolster CooperSurgical's capabilities in genetic testing, a critical area in infertility treatment. By integrating advanced genetic technologies, the company aims to offer more precise and effective solutions, thereby enhancing its market position.
As of November 2025, current trends in the infertility market include a strong emphasis on digitalization, sustainability, and the integration of AI technologies. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is expected to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift underscores the importance of developing unique value propositions that resonate with patients and healthcare providers alike.

## Recent News & Developments

In recent months, the France Infertility Market has witnessed significant movements, particularly involving key players such as Eugin Group and IBIS ART. Eugin Group announced an expansion of their services in May 2023, aiming to enhance patient access to IVF treatments across France. Fertility Network UK and the French Fertility Society have been collaborating on awareness campaigns to educate the public about fertility challenges, promoting a more informed approach towards treatment options.

Notably, IBIS ART has reported a valuation increase due to advancements in reproductive technology, contributing positively to the overall market dynamics. In terms of mergers and acquisitions, Clinique de la Femme was in talks regarding a potential merger with Fertinova in June 2023, enhancing their service portfolio. Toulouse Fertility Center has also seen growth in its market valuation driven by government support for fertility treatments, which was emphasized in the 2022 health initiative that allocated additional funds to reproductive health services.

These developments indicate a robust and evolving landscape in the French infertility sector, underscoring both corporate growth and increased public engagement in reproductive health issues.

## Report Scope

| MARKET SIZE 2024 | 91.59(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 103.3(USD Million) |
| MARKET SIZE 2035 | 344.2(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 12.79% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | CooperSurgical (US), Merck KGaA (DE), Ferring Pharmaceuticals (CH), Vitrolife (SE), Irvine Scientific (US), Reproductive Health Technologies (US), OvaScience (US), Genea (AU) |
| Segments Covered | Type, End User, Gender, Cause of Infertility |
| Key Market Opportunities | Emerging technologies in assisted reproductive techniques enhance accessibility in the infertility market. |
| Key Market Dynamics | Rising demand for advanced reproductive technologies drives innovation and competition in the infertility market. |
| Countries Covered | France |

## Frequently Asked Questions

**Q: What was the overall market valuation of the infertility market in 2024?**
A: The overall market valuation was $91.59 Million in 2024.

**Q: What is the projected market valuation for the infertility market by 2035?**
A: The projected valuation for 2035 is $344.2 Million.

**Q: What is the expected CAGR for the infertility market during the forecast period 2025 - 2035?**
A: The expected CAGR for the infertility market during the forecast period 2025 - 2035 is 12.79%.

**Q: Which segment had the highest valuation in 2024 within the infertility market?**
A: The Assisted Reproductive Technology segment had the highest valuation at $115.0 Million in 2024.

**Q: What are the key players in the infertility market?**
A: Key players include CooperSurgical, Merck KGaA, Ferring Pharmaceuticals, and Vitrolife.

**Q: How does the market valuation for fertility clinics compare to hospitals in 2024?**
A: In 2024, fertility clinics had a valuation of $150.0 Million, surpassing hospitals at $115.0 Million.

**Q: What was the valuation for male factor infertility in 2024?**
A: The valuation for male factor infertility was $124.2 Million in 2024.

**Q: Which gender segment shows a higher valuation in the infertility market?**
A: The male segment shows a higher valuation at $173.1 Million compared to the female segment at $171.1 Million.

**Q: What is the projected growth for the fertility preservation segment by 2035?**
A: The fertility preservation segment is expected to grow from $69.2 Million in 2024 to a higher valuation by 2035.

**Q: What causes of infertility had the highest valuations in 2024?**
A: Male factor infertility and tubal factors had the highest valuations at $124.2 Million and $90.0 Million, respectively, in 2024.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/france-infertility-market-45523*